One type of health care stock already has what everyone wants: transparent pricing, strong regulation, and direct competition to prevent price gouging.
[One type of health care stock already has what everyone wants: transparent pricing, strong regulation, and direct competition to prevent price gouging.]
The Only Health Care Stocks Immune to “Repeal and Replace”
[Adam English Photo] By [Adam English](
Written Saturday, March 11, 2017
Even the most polarizing figure in the world has bipartisan support on this one.
And in keeping with the times and person, a reminder came earlier this week in the form of an early morning tweet:
[trump tweet]
This is hardly the first time it has come up. Back in January, it was at a press conference where he stated, “They’re getting away with murder.”
Then there is the Time magazine interview. And all the campaign trail quotes.
And of course, there is the conspicuous, and auspicious timing, right as the House GOP unveiled the first phase of its repeal and replace for Obamacare, or the ACA, or whatever you want to call it.
Advertisement
101 Companies Offer a Secret $50 Retirement Plan
That Pays Up to $1.1 Million in Benefits
According to law, Microsoft, Cisco, Amgen, and other popular companies are NOT part of this retirement plan.
It’s a small pool of companies that offer you a chance to put up $50 (sometimes more) and watch it grow into hundreds of thousands of dollars, sometimes as much as $1.1 million in benefits, as some folks have made.
This plan is not advertised, and it's kept a secret by Congress. But anyone can legally take advantage of this unorthodox retirement plan.
[You can get the full details here.](
Meanwhile, renewed attention to astronomically high prices and questionable practices involving the orphan drug laws is getting attention from Congress as well.
Quite frankly, if health care costs are going to go down for individuals, states, and the federal government, there is no bigger issue.
And lets not kid ourselves. Drug companies know it too. They have been happy sitting right in the middle of the debate, shrugging off any challengers with the equivalent of, “well what are you going to do about it?”
For decades now, this has been a winning strategy, because no one has stepped forward with a good plan, or been willing to defy one of the most pervasive and powerful lobbying groups inside “The Beltway.”
But the fact remains that this is a wildly popular bipartisan issue, and one that can easily sweeten the deal for any elected official in the House or Senate.
Expect this to stay in the news for months as further details of repeal-and-replace come forward. There is no easier or better way to reduce health care spending across the board.
There is no way around the fact that it is a zero-sum game, and the pressure is mounting. Saving billions, as President Trump has repeatedly promised, for consumers means pulling them directly from the bottom lines of pharmaceutical and biotech companies.
[trump tweet stock drop]
Advertisement
Make Money on Every Electric Car in America
2,493 electric cars are sold every week...
And this is your chance to make money on every single one of them.
Step #1: Buy shares of a mining stock that supplies an extremely rare material every electric car MUST have.
Step #2: Ride the insatiable demand from Tesla, Toyota, Honda, Chevy, and the dozens of other companies consuming record amounts of this vital resource.
This mining stock has a unique supply advantage that could send its $1 shares climbing more than $8 in the weeks ahead.
[All the lucrative details are revealed in this new video.](
Every time it comes up, the vast majority of drug and medical device companies will drop like this, but not all of them.
The fastest growing segment of medical stocks are functionally immune.
They already adhere to President Trump’s — and virtually everyone else’s — goals: transparent pricing, strong regulation, and direct competition to prevent price gouging.
Medical cannabis is what we’re talking about here, and it is long past being contentious or fringe.
The North American cannabis market posted $6.7 billion in revenue in 2016, up a full 30% from 2015, according to a recent report from Arcview Market Research.
And that phenomenal growth isn’t an outlier. Arcview projects sales to grow at a compound annual growth rate of 25% through 2021.
At that point, it’s expected to be a $20.2 billion market.
Tom Adams, editor-in-chief of Arcview Market Research, said in a statement:
"The only consumer industry categories I've seen reach $5 billion in annual spending and then post anything like 25% compound annual growth in the next five years are cable television (19%) in the 1990s and the broadband internet (29%) in the 2000s.”
That’s right. The cannabis market is growing as fast as internet companies were in the 2000s.
Of course, the total market size won’t end up the same, no way, no how. But that hardly matters to us.
The growth rate of the companies, and thus the growth of the value of shareholder positions, will present an opportunity that rarely presents itself outside of full-blown paradigm shifts.
And all this is going to happen as prices are dropping due to the exact kind of competition and transparency that politicians on both sides of the aisle would kill to see in pharmaceutical prices.
For example, wholesale prices in Colorado tumbled 24.5% over just the past year.
Advertisement
This emerging technology just handed early investors
over 4,985%... and it's getting ready to do it again
At this very moment, an emerging technology is taking the world by storm, changing lives, and making early investors rich.
In fact, one stock just soared from $10 to $500, handing savvy investors a whopping 5,000%. That's good enough to turn a $25,000 investment into $1.25 million.
The best part? This is only the tip of the iceberg.
In fact, in the [following video](, I'll show you three stocks that have absolutely explosive upside potential and the ability to turn every $1 you invest into $10... $25... even $50 or more.
[Click here now]( to learn about these three stocks.
So far, we’ve only focused on North America, which functionally means the U.S.A. and Canada.
That certainly makes sense. Most of the companies are Canadian, considering the country has a much better defined and robust medical cannabis market dating back to court-mandated regulations between 1999 and 2001.
Same goes for most of the market in developed nations. The people, and more importantly the money to be made, has been almost entirely in North America.
That is changing fast, and international growth is accelerating as well. Just a couple months ago, Germany, by far the largest country in the European Union, passed a sweeping reform bill.
The German parliament voted unanimously to legalize medical marijuana in mid-January 2017, drastically simplify the prescription process, increase the number of eligible conditions, and have implemented policy that will provide health insurance coverage for patients.
Already, German pharmaceutical companies are looking to Canadian and U.S.-based companies to supply medical cannabis.
The infrastructure is in place, the leading businesses are well established, regulatory standards are high, and the price is right.
As strong as growth has been so far, this is just the start of it. We’re witnessing the creation of a whole new pharmaceutical sub-sector.
And while it has panned out, only one person I know has been covering it in depth.
In the last few years, Jimmy Mengel has become one of the world's best authorities on the subject of the North American cannabis industry — focusing specifically on the small start-ups that have sprung up around the opportunity.
He's going to hold a special presentation on March 14th about how to invest in this emerging market, targeting some of the most innovative companies operating today in any industry.
This presentation is open to anyone, but only if you register in advance. [Claim your spot as soon as possible](.
Just keep in mind there isn’t much time left to register for this free information, or to get in early on the medical cannabis market growth.
Changes this big don't happen often in the market, and they're not happening slowly.
Take care,
[Adam English]
Adam English
[follow basic]( [@AdamEnglishOC on Twitter](
Adam's editorial talents and analysis drew the attention of senior editors at [Outsider Club](, which he joined in mid-2012. While he has acquired years of hands-on experience in the editorial room by working side by side with ex-brokers, options floor traders, and financial advisors, he is acutely aware of the challenges faced by retail investors after starting at the ground floor in the financial publishing field. For more on Adam, check out his editor's [page](.
*Follow Outsider Club on [Facebook]( and [Twitter](.
Enjoy reading this article? [Click here]( to like it and receive similar articles to read!
Browse Our Archives
[Conservatism Is Dead… And So Is the Dollar](
[Market Correction Getting Serious](
[How to Increase Your Odds at a Gold Ten-Bagger](
[The War on Cash is a War on Freedom](
[Market Glitches and The Huge Assumption Hurting Investors](
Related Articles
[Marijuana Investors Have Nothing to Fear...](
[The President on Drugs](
[The Rise, Fall, and Rise of Legal Marijuana](
This email was sent to {EMAIL} . It is not our intention to send email to anyone who doesn't want it. If you're not sure why you've received this e-letter, or no longer wish to receive it, get more info [here](, including our privacy policy and information on how to manage your subscription.
To ensure that you receive future issues of Outsider Club, please add newsletter@outsiderclub.com to your address book or whitelist within your spam settings. For customer service questions or issues, please contact us for assistance.
[Outsider Club](, Copyright © 2017, [Angel Publishing LLC]( & Outsider Club LLC, 111 Market Place #720, Baltimore, MD 21202. For Customer Service, please call (877) 303-4529. All rights reserved. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. Angel Publishing and Outsider Club does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. This letter is not intended to meet your specific individual investment needs and it is not tailored to your personal financial situation. Nothing contained herein constitutes, is intended, or deemed to be – either implied or otherwise – investment advice. Neither the publisher nor the editors are registered investment advisors. This letter reflects the personal views and opinions of Nick Hodge and that is all it purports to be. While the information herein is believed to be accurate and reliable it is not guaranteed or implied to be so. Neither Nick Hodge, nor anyone else, accepts any responsibility, or assumes any liability, whatsoever, for any direct, indirect or consequential loss arising from the use of the information in this letter. The information contained herein is subject to change without notice, may become outdated and may not be updated. Nick Hodge, entities that he controls, family, friends, employees, associates, and others may have positions in securities mentioned, or discussed, in this letter. No part of this letter/article may be reproduced, copied, emailed, faxed, or distributed (in any form) without the express written permission of Nick Hodge or the Outsider Club. Unauthorized reproduction of this newsletter or its contents by Xerography, facsimile, or any other means is illegal and punishable by law.